Collegium Pharmaceutical, Inc. (COLL) Stock Score, Valuation & Financial Research
Collegium Pharmaceutical, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 58/100.
Quick answer for COLL
Collegium Pharmaceutical, Inc. currently has a Wall Street Score of 58/100. The stored market price is $22.19. Its financial score is 24/100. Its valuation score is 97/100. The latest WSS change is +1.8 points. These figures are a research snapshot, not a buy or sell recommendation.
What Collegium Pharmaceutical, Inc. does
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003
COLL financial snapshot
- Wall Street Score:
- 58/100
- Current price:
- $22.19
- Market capitalization:
- $719.7M
- Revenue:
- $808.2M
- Net income:
- $47.9M
- Free cash flow:
- $327.6M
- Cash:
- $129.5M
- Total debt:
- $857.8M
- EPS:
- 1.53
- P/E ratio:
- 14.5x
- Financial score:
- 24/100
- Valuation score:
- 97/100
- Revenue score:
- 38/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $327.6M, showing positive cash generation.
- The balance sheet shows $129.5M of cash versus $857.8M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +1.8 points: COLL increased 1.8 points because Capital improved by 2 points, Valuation improved by 4.4 points.
What the numbers mean
Its current valuation score is 97/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research COLL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.